Actinium Pharmaceuticals, Inc.

ATNM

Actinium Pharmaceuticals, Inc.

ATNM

Insider Sentiment (TTM):

Last Purchase:2018-12-10Last Sale:2016-08-31Shares Purchased (TTM):0Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:4,657,661Shares Outstanding:31,237,681Institutional Ownership Pct.:14.91%

Earnings Market Reaction:

Filing Date:2026-05-08Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Companies in Pharmaceutical Preparations

LLY JNJ ABBV MRK ABT PFE

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	42	48	53	60	65	73	79	86	84	77	83	91
Prepaid Expense And Other Assets Current	1	1	1	1	1	2	1	1	1	2	3	4
Assets Current	43	49	54	61	66	75	80	87	85	78	86	96
Property Plant And Equipment Net	0	0	0	0	0	0	0	0	0	1	1	1
Restricted Cash Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Operating Lease Right Of Use Asset	2	2	1	1	2	2	2	2	2	2	2	3
Finance Lease Right Of Use Asset	0	0	0	0	0	0	0	0	0	0	0	0
Assets	45	52	56	63	69	77	82	90	88	81	89	99
Liabilities And Stockhold…
Liabilities Current
Notes Payable Current	-	-	-	-	-	-	-	-	8	8	8	9
Accounts Payable And Accrued Liabilities Current	7	7	6	8	7	8	7	9	-	8	-	-
Operating Lease Liability Current	1	1	1	1	1	1	1	1	1	1	1	1
Finance Lease Liability Current	0	0	0	0	0	0	0	0	0	0	0	0
Liabilities Current	7	8	7	8	7	8	8	10	8	8	9	9
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	35
Deferred Revenue Noncurrent	-	-	-	-	-	-	-	-	35	35	35	-
Contract With Customer Liability Noncurrent	35	35	35	35	35	35	35	35	-	35	-	-
Operating Lease Liability Noncurrent	1	1	1	1	1	1	1	1	1	2	2	-
Finance Lease Liability Noncurrent	-	-	0	0	0	0	0	0	0	0	-	-
Liabilities	43	44	42	44	43	44	44	46	44	45	45	46
Stockholders Equity
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	418	418	418	418	417	409	407	401	390	374	372	368
Accumulated Other Comprehensive Income Loss Net Of…	-0	-0	-	-	-	-	-	-	-	-	-	-
Retained Earnings Accumulated Deficit	-415	-410	-404	-399	-392	-376	-369	-358	-346	-338	-328	-315
Stockholders Equity	2	8	14	19	26	33	38	44	44	36	44	53
Liabilities And Stockholders Equity	45	52	56	63	69	77	82	90	88	81	89	99
Accumulated Depreciation Depletion And Amortizatio…	1	1	1	1	1	1	1	1	1	1	1	1
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Preferred Stock Shares Authorized	100	100	100	100	100	100	100	100	100	100	100	100
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,000
Common Stock Shares Issued	31	31	31	31	31	31	31	31	29	28	27	27
Shares Outstanding	31	31	31	31	31	31	31	31	29	28	27	27

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-3.82%	-24.43%	-31.98%	-	-	-	-	-	-	-	-	-
2025	4.05%	-4.05%	20.95%	15.58%	4.55%	8.44%	12.60%	7.87%	-8.66%	29.29%	19.19%	4.04%
2024	42.65%	13.83%	8.44%	-19.76%	-27.42%	-32.26%	-17.58%	-12.73%	-29.70%	-18.63%	1.86%	-6.83%
2023	-7.38%	-19.35%	-24.05%	3.16%	-4.11%	-24.80%	-2.62%	15.94%	9.61%	-	-	-
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Metrics	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Liquidity Ratios
Current Ratio	5.89	6.20	7.96	7.34	9.35	9.14	10.25	8.95	10.59	9.21	9.87	10.44
Quick Ratio	5.73	6.02	7.81	7.21	9.19	8.95	10.14	8.84	10.42	9.03	9.57	9.97
Working Capital	35.91M	41.41M	47.53M	52.72M	59.35M	66.36M	71.77M	77.34M	77.31M	69.77M	76.92M	86.39M
Leverage & Debt
Debt to Equity	18.72	5.61	3.07	2.31	1.67	1.35	1.15	1.05	1.01	1.24	1.04	0.87
Interest Coverage TTM	-	-	-	-	-	-45.44	-23.10	-15.46	-14.34	-16.74	-19.39	-24.44
Debt Ratio	0.95	0.85	0.75	0.70	0.63	0.57	0.53	0.51	0.50	0.55	0.51	0.46
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-0.25	-0.36	-0.37	-0.44	-0.49	-0.42	-0.44	-0.47	-0.56	-0.61	-0.62	-0.59
Free Cash Flow Per Share TTM	-0.73	-0.79	-0.80	-0.98	-1.07	-1.10	-1.12	-1.13	-1.42	-1.78	-1.77	-1.62
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-28,346.67%	-40,274.44%	-41,486.67%	-	-	-	-	-	-	-	-	-107,368.89%
Net Profit Margin TTM	-26,078.89%	-37,652.22%	-38,443.33%	-	-	-	-	-	-	-	-	-102,975.56%
Growth Metrics
Net Revenue Growth (1Y)	-	-	-	-	-	-	-	-100.00%	-100.00%	-100.00%	-100.00%	-96.37%
Net Income Growth (1Y)	-48.43%	-11.39%	-15.44%	-3.72%	-2.02%	-21.66%	-18.40%	-8.02%	19.33%	47.86%	65.05%	69.56%
EPS Growth (1Y)	-48.50%	-14.59%	-15.77%	-7.10%	-12.42%	-30.69%	-28.94%	-19.89%	9.96%	34.17%	53.49%	53.48%
Valuation Metrics
P/E TTM	-1.32	-1.25	-1.44	-1.06	-1.10	-0.99	-1.43	-5.23	-4.70	-2.77	-3.19	-4.20
P/B TTM	13.49	5.42	3.62	2.30	1.95	1.16	1.53	5.08	4.98	3.72	3.68	3.67
P/S TTM	345.35	471.40	554.59	-	-	-	-	-	-	-	-	4,323.04
Market Cap	31.08M	42.43M	49.91M	43.67M	50.23M	37.89M	58.41M	222.76M	218.35M	135.15M	160.19M	194.54M
Enterprise Value	-11.38M	-5.90M	-3.80M	-16.57M	-15.41M	-35.32M	-20.54M	136.43M	141.52M	66.14M	85.05M	111.59M
Calculated Values
Free Cash Flow TTM	-22.88M	-24.58M	-25.04M	-30.69M	-33.27M	-33.08M	-34.82M	-34.00M	-39.72M	-47.49M	-47.79M	-42.43M
Net Debt	-42.46M	-48.32M	-53.71M	-60.24M	-65.63M	-73.21M	-78.96M	-86.33M	-76.83M	-69.01M	-75.14M	-82.94M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2018-12-10Purchase

Owner: O'Loughlin, Steve

Title: Principal Financial Officer

Shares: 10,000

Price/Share: $0.44

Value: $4,400.00

Shares Owned: 35,500

Relationship: Officer

Ownership: Direct

2018-12-10Purchase

Owner: Seth, Sandesh

Title: Chairman & CEO

Shares: 10,000

Price/Share: $0.44

Value: $4,400.00

Shares Owned: 153,333

Relationship: Director,Officer

Ownership: Direct

2018-11-19Purchase

Owner: Ludwig, Dale L.

Title: Chief Scientific Officer

Shares: 10,000

Price/Share: $0.45

Value: $4,500.00

Shares Owned: 10,000

Relationship: Officer

Ownership: Direct

2018-07-17Purchase

Owner: Seth, Sandesh

Title: CEO

Shares: 10,000

Price/Share: $0.79

Value: $7,900.00

Shares Owned: 143,333

Relationship: Director,Officer

Ownership: Direct

2018-06-15Purchase

Owner: O'Loughlin, Steve

Title: Principal Financial Officer

Shares: 12,000

Price/Share: $0.50

Value: $6,000.00

Shares Owned: 25,500

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2018-12-10	O'Loughlin, Steve	Officer	Principal Financial Officer	Direct	Purchase	10,000	0.44	$4,400.00	35,500	4
2018-12-10	Seth, Sandesh	Director,Officer	Chairman & CEO	Direct	Purchase	10,000	0.44	$4,400.00	153,333	4
2018-11-19	Ludwig, Dale L.	Officer	Chief Scientific Officer	Direct	Purchase	10,000	0.45	$4,500.00	10,000	4
2018-07-17	Seth, Sandesh	Director,Officer	CEO	Direct	Purchase	10,000	0.79	$7,900.00	143,333	4
2018-06-15	O'Loughlin, Steve	Officer	Principal Financial Officer	Direct	Purchase	12,000	0.50	$6,000.00	25,500	4
2018-04-19	Seth, Sandesh	Director,Officer	Chairman & CEO	Direct	Purchase	5,000	0.38	$1,900.00	133,333	4
2018-02-28	Shetty, Ajit	Director	-	Direct	Purchase	22,730	0.43	$9,773.90	22,730	4
2017-08-02	Seth, Sandesh	Director,Officer	Chairman & CEO	Direct	Purchase	33,333	0.75	$24,999.75	75,833	4
2017-08-02	Ray, Nitya G.	Officer	Executive Vice President	Direct	Purchase	10,000	0.75	$7,500.00	10,000	4
2017-06-15	O'Loughlin, Steve	Officer	Principal Financial Officer	Direct	Purchase	3,500	1.17	$4,095.00	3,500	4
2017-06-15	Berger, Mark Stanley	Officer	Chief Medical Officer	Direct	Purchase	5,000	1.11	$5,550.00	5,000	4
2017-06-15	Seth, Sandesh	Director,Officer	Chairman and CEO	Direct	Purchase	7,500	1.16	$8,700.00	42,500	4
2016-12-30	Seth, Sandesh	Director,Officer	Executive Chairman	Direct	Purchase	5,000	0.88	$4,400.00	35,000	4
2016-12-12	Seth, Sandesh	Director,Officer	Executive Chairman	Direct	Purchase	5,000	0.98	$4,900.00	30,000	4
2016-08-31	Memorial, Sloan-Kettering…	TenPercentOwner	-	Direct	Sale	136,853	1.83	$250,440.99	4,709,561	4
2016-08-29	Memorial, Sloan-Kettering…	TenPercentOwner	-	Direct	Sale	25,000	1.72	$43,000.00	4,902,488	4
2016-08-16	Memorial, Sloan-Kettering…	TenPercentOwner	-	Direct	Sale	5,029	1.72	$8,649.88	4,952,488	4
2016-07-12	Memorial, Sloan-Kettering…	TenPercentOwner	-	Direct	Sale	3,100	1.81	$5,611.00	4,961,956	4
2016-07-11	Memorial, Sloan-Kettering…	TenPercentOwner	-	Direct	Sale	800	1.80	$1,440.00	4,965,056	4
2016-07-06	Memorial, Sloan-Kettering…	TenPercentOwner	-	Direct	Sale	10,500	1.80	$18,900.00	4,987,046	4
2016-07-01	Memorial, Sloan-Kettering…	TenPercentOwner	-	Direct	Sale	128,950	1.84	$237,268.00	5,007,886	4
2016-06-15	Memorial, Sloan-Kettering…	TenPercentOwner	-	Direct	Sale	33,619	1.90	$63,876.10	5,155,986	4
2016-06-02	Memorial, Sloan-Kettering…	TenPercentOwner	-	Direct	Sale	17,790	2.01	$35,757.90	5,189,605	4
2016-06-01	Memorial, Sloan-Kettering…	TenPercentOwner	-	Direct	Sale	40,114	2.08	$83,437.12	5,207,395	4
2016-05-26	Memorial, Sloan-Kettering…	TenPercentOwner	-	Direct	Sale	40,068	1.93	$77,331.24	5,376,845	4
2016-05-25	Memorial, Sloan-Kettering…	TenPercentOwner	-	Direct	Sale	36,400	1.91	$69,524.00	5,416,913	4
2016-04-26	Memorial, Sloan-Kettering…	TenPercentOwner	-	Direct	Sale	6,500	1.96	$12,740.00	5,453,313	4
2016-04-21	Memorial, Sloan-Kettering…	TenPercentOwner	-	Direct	Sale	13,000	2.04	$26,520.00	5,505,890	4
2016-04-18	Seth, Sandesh	DirectorOther	-	Direct	Purchase	6,500	1.98	$12,870.00	25,000	4
2016-04-15	Traversa, Sergio	Director	-	Direct	Purchase	1,000	2.02	$2,020.00	3,000	4
2016-04-14	Dave, Kaushik J	Director,Officer	CEO and Interim CFO	Direct	Purchase	10,000	2.01	$20,100.00	88,500	4
2016-04-14	Steinhart, Richard I	Director	-	Direct	Purchase	2,500	2.01	$5,025.00	2,500	4
2016-04-14	Nicholson,, C. David	Director	-	Direct	Purchase	5,000	2.00	$10,000.00	15,000	4
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

14.91%

Inst. Shares: 4,657,661

Shares Outstanding: 31,237,681

2025-12-31

15.26%

Inst. Shares: 4,761,827

Shares Outstanding: 31,195,891

2025-09-30

14.93%

Inst. Shares: 4,656,362

Shares Outstanding: 31,195,891

2025-06-30

15.80%

Inst. Shares: 4,927,940

Shares Outstanding: 31,195,891

2025-03-31

24.31%

Inst. Shares: 7,582,204

Shares Outstanding: 31,195,891

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	4,657,661	31,237,681	14.91%
2025-12-31	4,761,827	31,195,891	15.26%
2025-09-30	4,656,362	31,195,891	14.93%
2025-06-30	4,927,940	31,195,891	15.80%
2025-03-31	7,582,204	31,195,891	24.31%
2024-12-31	7,544,724	30,070,028	25.09%
2024-09-30	7,924,058	31,071,297	25.50%
2024-06-30	7,104,873	30,103,063	23.60%
2024-03-31	6,517,769	27,886,486	23.37%
2023-12-31	5,633,144	26,604,045	21.17%
2023-09-30	5,728,389	27,058,397	21.17%
2023-06-30	5,902,780	26,217,910	22.51%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Actinium Pharmaceuticals, Inc. (ATNM) — SEC Financial Statements & Analysis

Actinium Pharmaceuticals, Inc. (ATNM) is a pharmaceutical preparations company, incorporated in DE. Actinium Pharmaceuticals, Inc. trades on NYSE as: ATNM. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), Actinium Pharmaceuticals, Inc. reported a -100.00% year-over-year revenue growth, a Debt-to-Equity ratio of 18.72x, a Price-to-Sales (P/S) ratio of 345.35x (TTM), a Price-to-Book (P/B) ratio of 13.49 (TTM), at a market cap of $31.08M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -100.00%
Debt To Equity: 18.72x
P/S TTM: 345.35x
P/B TTM: 13.49
Market Cap: $31.08M

Data as of 2026-03-31 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Actinium Pharmaceuticals, Inc. in?

Actinium Pharmaceuticals, Inc. (ATNM) operates in the Pharmaceutical Preparations industry.

What is ATNM's market cap?

Actinium Pharmaceuticals, Inc. (ATNM) has a market capitalization of $31.08M as of 2026-03-31.

What exchange does ATNM trade on?

Actinium Pharmaceuticals, Inc. (ATNM) trades on the NYSE.

Where is Actinium Pharmaceuticals, Inc. incorporated?

Actinium Pharmaceuticals, Inc. is incorporated in DE.

Actinium Pharmaceuticals, Inc. (ATNM) — SEC Financial Statements & Analysis

Frequently Asked Questions

Research Faster.Invest Smarter.

Research Faster.
Invest Smarter.